表紙
市場調査レポート

抗菌薬の世界市場:2015〜2019年

Global Antibacterial Drugs Market 2015-2019

発行 TechNavio (Infiniti Research Ltd.) 商品コード 345157
出版日 ページ情報 英文 116 Pages
即納可能
価格
本日の銀行送金レート: 1USD=105.42円で換算しております。
Back to Top
抗菌薬の世界市場:2015〜2019年 Global Antibacterial Drugs Market 2015-2019
出版日: 2015年11月11日 ページ情報: 英文 116 Pages
概要

抗菌薬は抗生剤と同義語として用いられ、細菌を死滅または増殖を阻害することで最近による感染症を治療するための化学化合物です。細菌、真菌、寄生虫などの微生物に効果がありますが、ウイルスには有効ではありません。世界の抗菌薬市場は2014〜2019年にかけCAGR1.06%で拡大すると予測されています。

当レポートでは、世界の抗菌薬市場について調査し、地域別動向、今後の市場成長見込み、2019年の市場規模予測、市場成長の課題、主要ベンダーの動向などをまとめています。

第1章 エグゼクティブサマリー

第2章 当レポートの範囲

第3章 市場調査方法

第4章 イントロダクション

第5章 抗菌薬:概要

  • イントロダクション
  • 作用機序
  • 抗生剤の使用のための一般的原則
  • 臨床における使用
  • 疫学

第6章 パイプライン分析

第7章 抗菌薬への耐性

第8章 米国における抗生剤使用に関する法規制

第9章 市場環境

  • 市場概要
  • 市場規模と予測
  • ファイブフォース分析

第10章 化学クラス別市場セグメンテーション

  • βラクタム
  • アミノグリコシド
  • フェニコール
  • キノロン
  • 葉酸拮抗剤
  • テトラシクリン
  • その他

第11章 薬剤源別市場セグメンテーション

  • 天然
  • 半合成
  • 合成

第12章 作用機序別市場セグメンテーション

  • 静菌性
  • 殺菌性

第13章 作用範囲別市場セグメンテーション

  • 広域
  • 狭域

第14章 地域別セグメンテーション

  • 地域別セグメンテーション
  • アジア太平洋地域
  • 欧州・中東・アフリカ
  • 南北アメリカ

第15章 市場促進因子

  • 法規制による特別な指定
  • 感染症の蔓延
  • 意識向上
  • 高齢化

第16章 促進因子の影響

第17章 市場の課題

  • 薬剤耐性株の開発
  • 特許失効とジェネリックの参入
  • 研究活動における投資減少

第18章 促進因子と課題の影響

第19章 市場動向

  • 戦略的提携とM&A
  • 患者支援プログラム
  • 抗生剤研究に対する資金増加

第20章 ベンダー環境

  • 競合シナリオ
  • 2014年の市場シェア分析
  • その他の注目すべきベンダー

第21章 主要ベンダー分析

  • Allergan
  • GSK
  • Merck
  • Pfizer
  • Sandoz
  • Teva Pharmaceuticals

第22章 付録

第23章 Techvavioについて

図表

目次
Product Code: IRTNTR7883

About antibacterial drugs

Antibacterial drugs are chemical compounds used to treat infections caused by bacteria either by killing or inhibiting the growth of bacteria. The term antibiotic is often used synonymously with an antibacterial. However, antibiotics are agents that work against microorganisms such as bacteria, fungi, and parasites but are not effective against viruses. The term antibiotic was originally coined to refer to any compound of microbial origin, which is antagonistic to the growth of the microbe. Antibacterial acts via various mechanisms such as the inhibition of cell wall synthesis, the inhibition of nucleic acid synthesis, the disruption of the cell membrane, and the inhibition of protein synthesis. They can be bacteriostatic or bactericidal in nature, i.e., they either block vital processes in bacteria, kill the bacteria, or halt them from growing. Antibiotics that affect a wide range of bacteria are called broad-spectrum antibiotics (e.g., amoxicillin and gentamicin). Antibiotics that affect only a few types of bacteria are called narrow spectrum antibiotics (e.g., penicillin).

Technavio's analysts forecast the global antibacterial drugs market to grow at a CAGR of 1.06% over the period 2014-2019.

Covered in this report

In this report, Technavio covers the present scenario and growth prospects of the global antibacterial drugs market for 2015-2019. To calculate the market size, the report considers revenue generated from the sales of various prescription drugs along with the generic drugs used for the treatment of various infectious diseases caused by the different strains of bacteria. The various classes of antibacterial drug included in this report are beta-lactams, macrolides, aminoglycosides, phenicols, quinolones, folate antagonists, tetracyclines, and other miscellaneous agents, which include glycopeptides, nitroimidazoles, lincosamides, lipopeptides, nicotinic acid derivatives, and polypeptide antibiotics.

Technavio's report, Global Antibacterial Drugs Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, APAC, and EMEA; it also covers the landscape of the global antibacterial drugs market and its growth prospects in the coming years. The report includes a discussion of the key vendors operating in this market.

Key regions

  • Americas
  • APAC
  • EMEA

Key vendors

  • Allergan
  • GlaxoSmithKline
  • Merck
  • Novartis
  • Pfizer
  • Teva Pharmaceuticals

Other Prominent Vendors

  • Abbott
  • Achaogen
  • Actelion
  • AmpliPhi Biosciences
  • Aspen Pharmacare
  • Astellas
  • AstraZeneca
  • Aurobindo Pharma
  • Baxter
  • Basilea Pharmaceuticals
  • Bayer
  • Biocon
  • Bristol-Myers Squibb
  • Cempra
  • Cipher Pharmaceuticals
  • Corden Pharma
  • Cornerstone Therapeutics
  • Eli Lilly
  • Exoxemis
  • F. Hoffmann-La Roche
  • Flynn Pharma
  • Hospira
  • Incepta Pharmaceuticals
  • InSite Vision
  • Insmed Incorporated
  • Johnson & Johnson
  • KaloBios Pharmaceuticals
  • Kyorin Pharmaceutical
  • Lupin Pharmaceuticals
  • Lytix Biopharma
  • Melinta Therapeutics
  • Mylan
  • Nektar
  • Orchid Pharma
  • Par Pharmaceutical
  • Paratek Pharmaceuticals
  • Pernix Therapeutics
  • PTC Therapeutics
  • RedHill Biopharma
  • Sagent Pharmaceuticals
  • Sanofi
  • Shionogi
  • Starpharma
  • Sun Pharmaceutical
  • Symbiomix
  • Takeda Pharma
  • Tetraphase Pharmaceuticals
  • Theravance Biopharma
  • The Medicines Company
  • Valneva
  • Wockhardt Global Solutions

Key market driver

  • Special regulatory designations
  • For a full, detailed list, view our report

Key market challenge

  • Development of drug-resistant strains
  • For a full, detailed list, view our report

Key market trend

  • Strategic alliances and M&A
  • For a full, detailed list, view our report

Key questions answered in this report

  • What will the market size be in 2019 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?

Table of Contents

PART 01: Executive summary

  • Highlights

PART 02: Scope of the report

  • Market overview
  • Top-vendor offerings

PART 03: Market research methodology

  • Research methodology
  • Economic indicators

PART 04: Introduction

  • Key market highlights

PART 05: Antibacterial: overview

  • Introduction
  • Mechanism of action
  • General principles for the use of antibiotics
  • Clinical uses
  • Epidemiology

PART 06: Pipeline analysis

  • Zerbaxa
  • Surotomycin
  • MK-3415A
  • Amikacin Inhale
  • CARBAVANCE
  • Eravacycline
  • Plazomicin
  • Delafloxacin
  • Solithromycin
  • VivaGel
  • Arikayce
  • Cadazolid
  • Ozenoxacin

PART 07: Antimicrobial resistance

  • Sources of spread of resistant organisms
  • Initiatives to improve antibiotic innovation

PART 08: Legislation relating to antibiotic use in the US

PART 09: Market landscape

  • Market overview
  • Market size and forecast
  • Five forces analysis

PART 10: Market segmentation by chemical class

  • Beta-lactam
  • Macrolides
  • Aminoglycosides
  • Phenicols
  • Quinolones
  • Folate antagonists
  • Tetracyclines
  • Others

PART 11: Market segmentation by drug origin

  • Natural
  • Semisynthetic
  • Synthetic

PART 12: Market segmentation by mechanism of action

  • Bacteriostatic
  • Bactericidal

PART 13: Market segmentation by spectrum of activity

  • Broad spectrum antibiotics
  • Narrow spectrum antibiotics

PART 14: Geographical segmentation

  • Global antibacterial drugs market by geographical segmentation 2014-2019
  • Antibacterial drugs market in APAC
  • Antibacterial drugs market in EMEA
  • Antibacterial drugs market in Americas

PART 15: Market drivers

  • Special regulatory designations
  • Increase in prevalence of infections
  • Increase in awareness
  • Increase in aging population

PART 16: Impact of drivers

PART 17: Market challenges

  • Development of drug resistant strains
  • Patent expiries and generic penetration
  • Decreased investments in research activities

PART 18: Impact of drivers and challenges

PART 19: Market trends

  • Strategic alliances and M&A
  • Patient assistance programs
  • Increased funding on antibiotic research

PART 20: Vendor landscape

  • Competitive scenario
  • Market share analysis 2014
  • Other prominent vendors

PART 21: Key vendor analysis

  • Allergan
  • GSK
  • Merck
  • Pfizer
  • Sandoz
  • Teva Pharmaceuticals

PART 22: Appendix

  • List of abbreviation

PART 23: Explore Technavio

List of Exhibits

  • Exhibit 01: Product offerings
  • Exhibit 02: Mechanism of action of antibacterial drugs
  • Exhibit 03: General principles involved in the use of antibiotics
  • Exhibit 04: Estimated number of cases for nosocomial infections in US, 2011
  • Exhibit 05: Number of cases for Escherichia coli bacteremia in UK, 2012-2014
  • Exhibit 06: Global antibacterial drugs market: Pipeline portfolio
  • Exhibit 07: Causes of antimicrobial resistance
  • Exhibit 08: Sources of spread of resistant organisms
  • Exhibit 09: Estimated deaths per year caused by AMR in 2050
  • Exhibit 10: Initiatives improving antibiotic innovation
  • Exhibit 11: Legislation relating to antibiotic use in US
  • Exhibit 12: Global antibacterial drugs market 2014-2019 ($ billions)
  • Exhibit 13: Five forces analysis
  • Exhibit 14: Global antibacterial drugs market segmentation by chemical class
  • Exhibit 15: Cephalosporin segmentation by generation of drugs
  • Exhibit 16: Global antibacterial drugs market revenue segmentation by chemical class
  • Exhibit 17: Global antibacterial drugs market segmentation by drug origin
  • Exhibit 18: Global antibacterial drugs market segment by geography 2014
  • Exhibit 19: Antibacterial drugs market revenue by geography 2014-2019 ($ billions)
  • Exhibit 20: Antibacterial drugs market in APAC 2014-2019 ($ billions)
  • Exhibit 21: Antibacterial drugs market in EMEA 2014-2019 ($ billions)
  • Exhibit 22: Antibacterial drugs market in Americas 2014-2019 ($ billions)
  • Exhibit 23: Percentage share of antibacterial drugs market in Americas
  • Exhibit 24: Impact of drivers
  • Exhibit 25: Antibiotic-resistant strains according to the period of development of resistance
  • Exhibit 26: Antibacterial drug approvals by FDA and EMA
  • Exhibit 27: Impact of drivers and challenges
  • Exhibit 28: Allergan: YoY growth and revenue generated from net product sales of anti-infective 2011-2013 ($ millions)
  • Exhibit 29: Allergan: Key takeaways
  • Exhibit 30: GlaxoSmithKline: YoY growth and revenue generated from sales of Augmentin 2011-2014 ($ millions)
  • Exhibit 31: GlaxoSmithKline: Revenue generated from sales of Augmentin by region 2011-2014 ($ millions)
  • Exhibit 32: GlaxoSmithKline: YoY growth and revenue generated from sales of other antibacterials 2011-2013 ($ millions)
  • Exhibit 33: GlaxoSmithKline: Key takeaways
  • Exhibit 34: Merck: YoY growth and revenue generated from sales of Primaxin 2012-2014 ($ millions)
  • Exhibit 35: Merck: YoY growth and revenue generated from sales of Invanz 2012-2014 ($ millions)
  • Exhibit 36: Merck: Key takeaways
  • Exhibit 37: Pfizer: YoY growth and revenue generated from sales of Zyvox 2012-2014 ($ millions)
  • Exhibit 38: Pfizer: YoY growth and revenue generated from sales of Zithromax/Zmax 2012-2014 ($ millions)
  • Exhibit 39: Pfizer: YoY growth and revenue generated from sales of Unasyn 2012-2014 ($ millions)
  • Exhibit 40: Pfizer: YoY growth and revenue generated from sales of Zosyn/Tazocin 2012-2014 ($ millions)
  • Exhibit 41: Pfizer: YoY growth and revenue generated from sales of Sulperazon 2012-2014 ($ millions)
  • Exhibit 42: Pfizer: YoY growth and revenue generated from sales of Tygacil 2012-2014 ($ millions)
  • Exhibit 43: Pfizer: Key takeaways
  • Exhibit 44: Sandoz: Key takeaways
  • Exhibit 45: Teva Pharmaceuticals: Key takeaways
  • Exhibit 46: Allergan: Business segmentation by product revenue 2014
  • Exhibit 47: Allergan: Business segmentation by revenue 2013 and 2014 ($ billions)
  • Exhibit 48: Allergan: Geographical segmentation by revenue 2014
  • Exhibit 49: GSK: Business segmentation by revenue 2014
  • Exhibit 50: GSK: Business segmentation by revenue 2013 and 2014 ($ billions)
  • Exhibit 51: GSK: Geographical segmentation by revenue 2014
  • Exhibit 52: Merck: Business segmentation by revenue 2014
  • Exhibit 53: Merck: Business segmentation by revenue 2013 and 2014 ($ billions)
  • Exhibit 54: Merck: Geographical segmentation by revenue 2014
  • Exhibit 55: Pfizer: Business segmentation by revenue 2014
  • Exhibit 56: Pfizer business segmentation by revenue 2013 and 2014 ($ billions)
  • Exhibit 57: Pfizer: Geographical segmentation by revenue 2014
  • Exhibit 58: Sandoz: Business segmentation by revenue 2014
  • Exhibit 59: Teva Pharmaceuticals: Business segmentation by revenue 2014
  • Exhibit 60: Teva Pharmaceuticals: Business segmentation by revenue 2013 and 2014
  • Exhibit 61: Teva Pharmaceuticals: Geographical segmentation by revenue 2014
Back to Top